Journal
SMALL
Volume 19, Issue 10, Pages -Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/smll.202206415
Keywords
cobaltous oxide; dendritic mesoporous silica; ferroptosis; heme oxygenase 1; radiotherapy sensitizers
Ask authors/readers for more resources
In this study, an anticancer regimen that increases intratumoral cobalt (Co) levels through targeted nanomaterial delivery is proposed. Cobaltous oxide nanodots are prepared using a facile biomineralization strategy with bovine serum albumin and cobalt dichloride. After iRGD peptide conjugation, the nanodots are loaded into dendritic mesoporous silica nanoparticles to generate a biocompatible product iCoDMSN. This versatile nanocomposite accumulates in tumors and acts as an efficient radiotherapy enhancer by priming ferroptosis.
High cobalt (Co) levels in tumors are associated with good clinical prognosis. An anticancer regimen that increases intratumoral Co through targeted nanomaterial delivery is proposed in this study. Bovine serum albumin and cobalt dichloride are applied to prepare cobaltous oxide nanodots using a facile biomineralization strategy. After iRGD peptide conjugation, the nanodots are loaded into dendritic mesoporous silica nanoparticles, generating a biocompatible product iCoDMSN. This nanocomposite accumulates in tumors after intravenous injection by deep tissue penetration and can be used for photoacoustic imaging. Proteomics research and molecular biology experiments reveal that iCoDMSN is a potent ferroptosis inducer in cancer cells. Mechanistically, iCoDMSNs upregulate heme oxygenase 1 (HMOX1), which increases transferrin receptors and reduces solute carrier family 40 member 1 (SLC40A1), resulting in Fe2+ accumulation and ferroptosis initiation. Furthermore, upregulated nuclear factor erythroid 2-related factor 2 (NRF2), arising from the reduction in Kelch-like ECH-associated protein 1 (KEAP1) expression, is responsible for HMOX1 enhancement after iCoDMSN treatment. Owing to intensified ferroptosis, iCoDMSN acts as an efficient radiotherapy enhancer to eliminate cancer cells in vitro and in vivo. This study demonstrates a versatile Co-based nanomaterial that primes ferroptosis by expanding the labile iron pool in cancer cells, providing a promising tumor radiotherapy sensitizer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available